Delray Beach, Fla. – September 11, 2026 -- The global active wound care market will expand from $3.19 billion in 2026 to $4.50 billion by 2031, a 7.1% compound annual growth rate, according to a new MarketsandMarkets report.
Biological skin substitutes command 56.8% of 2025 product-type revenue
Biological skin substitutes, derived from human donor tissue and animal sources, held the largest share of the market by product type in 2025 at 56.8%, driven by expanding clinical evidence for tissue regeneration and use in diabetic foot ulcers, venous leg ulcers, pressure injuries, and burns.
Chronic wounds and hospitals dominate demand
Chronic wounds accounted for the largest share by wound type in 2025, reflecting prolonged treatment cycles and high recurrence linked to diabetic foot ulcers and pressure injuries. Hospitals led end-user demand the same year, handling debridement, grafting, and reconstructive procedures that require advanced wound matrices.
North America controls 44.9% of global market share
North America accounted for 44.9% of the global active wound care market in 2025, supported by reimbursement availability, established wound-care infrastructure, and the concentration of manufacturers including Smith+Nephew, Organogenesis, MIMEDX, Integra LifeSciences, Coloplast, ConvaTec, Solventum, Stryker, and Anika Therapeutics.
M&A activity intensifies around regenerative platforms
Coloplast's 2023 acquisition of Kerecis for up to $1.3 billion, including $1.2 billion upfront, opened the Danish group's entry into US biologics wound care through fish-skin regenerative technology. Solventum closed its purchase of Acera Surgical in December 2025 for $725 million in cash plus up to $125 million in contingent payments, adding electrospun synthetic tissue matrices for acute-care use. MIMEDX agreed in July 2026 to acquire Sanara MedTech at an enterprise value of approximately $350 million, backed by a $300 million committed term loan from Hayfin Capital Management.
Growth-stage firms tap debt financing for capacity expansion
AVITA Medical secured a five-year credit facility of up to $60 million from Perceptive Adv